Come on finish 1.60 plus, page-475

Wilson’s bullish

TELA Bio | 2Q24| Investment ViewTELA Bio (TELA) missed estimates in 2Q24, reporting US$16.1M OviTex revenue (WILSe:US$18.4M) but maintained full year guidance at US$74.5-76.5M. Similar but independent cyber-attacks impacted a national GPO and hospital customer, impacting revenue by ~US$1.5-2.0M.We maintain OVERWEIGHT rating and $1.00 PT on Aroa Biosurgery. Minimal impact to ARX.| Announcement HighlightsAroa’s US channel partner TELA Bio released 2Q24 results. OviTex revenue of US$16.1M was below our forecast (WILSe: US$18.4M) representing11% growth vs pcp. The FY24 revenue guidance range was maintained, noting a recovery in volumes in 3Q. The impacted GPO (Ascension) was arelatively new channel partner and growing quickly. The incident emerged in early May and was resolved within a few weeks. TELA estimates an impactof US$1.25-1.75M from this event. Separately, a large hospital customer